Guidelines for the treatment and management of new-onset diabetes after transplantation
Authors: Wilkinson, Alan1; Davidson, Jaime2; Dotta, Francesco3; Home, Philip D4; Keown, Paul5; Kiberd, Bryce6; Jardine, Alan7; Levitt, Naomi8; Marchetti, Piero9; Markell, Mariana10; Naicker, Sarala11; O'Connell, Philip12; Schnitzler, Mark13; Standl, Eberhard14; Jose-VicenteTorregosa15; Uchida, Kazuharu16; Valantine, Hannah17; Villamil, Federico18; Vincenti, Flavio19; Wissing, Martin20
Source: Clinical Transplantation, Volume 19, Number 3, June 2005 , pp. 291-298(8)
Publisher: Blackwell Publishing
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
Wilkinson A, Davidson J, Dotta F, Home PD, Keown P, Kiberd B, Jardine A, Levitt N, Marchetti P, Markell M, Naicker S, O'Connell P, Schnitzler M, Standl E, Torregosa J-V, Uchida K, Valantine H, Villamil F, Vincenti F, Wissing M. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005 DOI: 10.1111/j.1399-0012.2005.00359.x © Blackwell Munksgaard, 2005 Abstract: Although graft and patient survival after solid organ transplantation have improved markedly in recent years, transplant recipients continue to experience an increased prevalence of cardiovascular disease (CVD) compared with the general population. A number of factors are known to impact on the increased risk of CVD in this population, including hypertension, dyslipidemia and diabetes mellitus. Of these factors, new-onset diabetes after transplantation has been identified as one of the most important, being associated with reduced graft function and patient survival, and increased risk of graft loss. In 2003, International Consensus Guidelines on New-onset Diabetes after Transplantation were published, which aimed to establish a precise definition and diagnosis of the condition and recommend management strategies to reduce its occurrence and impact. These updated 2004 guidelines, developed in consultation with the International Diabetes Federation (IDF), extend the recommendations of the previous guidelines and encompass new-onset diabetes after kidney, liver and heart transplantation. It is hoped that adoption of these management approaches pre- and post-transplant will reduce individuals’ risk of developing new-onset diabetes after transplantation as well as ameliorating the long-term impact of this serious complication.Keywords: calcineurin inhibitors; cyclosporine; dyslipidemia; hyperglycemia; immunosuppression; impaired glucose tolerance; new-onset diabetes; tacrolimus; transplantation
Document Type: Review article
DOI: 10.1111/j.1399-0012.2005.00359.x
Affiliations: 1: David Geffen School of Medicine at UCLA, Los Angeles, CA 2: Endocrine and Diabetes Association of Texas, University of Texas Southwestern Medical School, Dallas, TX, USA 3: University of Rome, Rome, Italy 4: Department of Diabetes and Metabolism, University of Newcastle Medical School, Newcastle upon Tyne, UK 5: Vancouver General Hospital, Vancouver, BC, Canada 6: Dalhousie University, Halifax, NS, Canada 7: University of Glasgow, Western Infirmary, Glasgow, UK 8: University of Cape Town, Groote Schuur Hospital, Cape Town, South Africa 9: University of Pisa, Pisa, Italy 10: SUNY Downstate Medical Center, New York, NY, USA 11: University of the Witwatersrand, Johannesburg, South Africa 12: Westmead Hospital, Westmead, Australia 13: Washington University School of Medicine, St Louis, MO, USA 14: Diabetes Research Institute, Munich, Germany 15: Hospital Clinic, University of Barcelona, Barcelona, Spain 16: Nagoya Daini Red Cross Hospital, Nagoya, Japan 17: Stanford University, Stanford, CA, USA 18: Unidad de Higado, Buenos Aires, Argentina 19: University of California, San Francisco, CA, USA 20: ULB-Hopital Erasme, Brussels, Belgium
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Click here for Page Help